These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36856777)

  • 1. Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort.
    Karakas C; Tyburski H; Turner BM; Wang X; Schiffhauer LM; Katerji H; Hicks DG; Zhang H
    Am J Clin Pathol; 2023 May; 159(5):484-491. PubMed ID: 36856777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Dako HercepTest and Ventana PATHWAY Anti-HER2 (4B5) Tests and Their Correlation With Fluorescent In Situ Hybridization in Breast Carcinoma.
    Lucas E; Jabbar SB; Molberg K; Fang Y; Xie XJ; Blacketer S; Sahoo S
    Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):403-409. PubMed ID: 31233398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of HercepTest™ mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status.
    Rüschoff J; Friedrich M; Nagelmeier I; Kirchner M; Andresen LM; Salomon K; Portier B; Sredni ST; Schildhaus HU; Jasani B; Grzelinski M; Viale G
    Virchows Arch; 2022 Nov; 481(5):685-694. PubMed ID: 35970977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interobserver reproducibility for HER2/neu immunohistochemistry: A comparison of reproducibility for the HercepTest™ and the 4B5 antibody clone.
    Layfield LJ; Frazier S; Esebua M; Schmidt RL
    Pathol Res Pract; 2016 Mar; 212(3):190-5. PubMed ID: 26839158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of HER2 DAKO HercepTest and Ventana 4B5 immunohistochemical assays on detecting HER2 gene-amplification in uterine serous carcinomas.
    Navarro Sanchez JM; Finkelman BS; Tyburski H; Turner BM; Moisini I; Katerji H; Varghese S; Wang X; Schiffhauer LM; Chen JJ; Hicks DG; Zhang H
    Hum Pathol; 2024 Jun; 148():51-59. PubMed ID: 38740270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
    Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
    World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
    Powell WC; Hicks DG; Prescott N; Tarr SM; Laniauskas S; Williams T; Short S; Pettay J; Nagle RB; Dabbs DJ; Scott KM; Brown RW; Grogan T; Roche PC; Tubbs RR
    Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):94-102. PubMed ID: 17536315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma.
    Tsuda H; Sasano H; Akiyama F; Kurosumi M; Hasegawa T; Osamura RY; Sakamoto G
    Pathol Int; 2002 Feb; 52(2):126-34. PubMed ID: 11940217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.
    van der Vegt B; de Bock GH; Bart J; Zwartjes NG; Wesseling J
    Mod Pathol; 2009 Jul; 22(7):879-86. PubMed ID: 19305385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a HER2-Low Focused Immunohistochemical Scoring System With High-Interobserver Concordance: The Australian HER2-Low Breast Cancer Concordance Study.
    Farshid G; Armes J; Dessauvagie B; Gilhotra A; Kumar B; Mahajan H; Millar E; Pathmanathan N; Snell C
    Mod Pathol; 2024 Aug; 37(8):100535. PubMed ID: 38852812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.
    Robbins CJ; Fernandez AI; Han G; Wong S; Harigopal M; Podoll M; Singh K; Ly A; Kuba MG; Wen H; Sanders MA; Brock J; Wei S; Fadare O; Hanley K; Jorns J; Snir OL; Yoon E; Rabe K; Soong TR; Reisenbichler ES; Rimm DL
    Mod Pathol; 2023 Jan; 36(1):100032. PubMed ID: 36788069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intralaboratory reproducibility of HER2 testing in breast cancer by immunohistochemistry and comparison of results obtained by different assays].
    Yang Y; Wei B; Zhang Z; Tang Y; Fu J; Liao DY; Li FY; Bu H
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):29-34. PubMed ID: 19489222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
    Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
    Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
    Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
    J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.
    Gouvêa AP; Milanezi F; Olson SJ; Leitao D; Schmitt FC; Gobbi H
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):103-8. PubMed ID: 16540740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.
    Garrido C; Manoogian M; Ghambire D; Lucas S; Karnoub M; Olson MT; Hicks DG; Tozbikian G; Prat A; Ueno NT; Modi S; Feng W; Pugh J; Hsu C; Tsurutani J; Cameron D; Harbeck N; Fang Q; Khambata-Ford S; Liu X; Inge LJ; Vitazka P
    Virchows Arch; 2024 Jun; 484(6):1005-1014. PubMed ID: 37857998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
    Sun H; Kang EY; Chen H; Sweeney KJ; Suchko M; Wu Y; Wen J; Krishnamurthy S; Albarracin CT; Ding QQ; Foo WC; Sahin AA
    Breast Cancer Res Treat; 2024 Jun; 205(2):403-411. PubMed ID: 38441847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive immunohistochemical analysis of Her-2/neu oncoprotein overexpression in breast cancer: HercepTest (Dako) for manual testing and Her-2/neuTest 4B5 (Ventana) for Ventana BenchMark automatic staining system with correlation to results of fluorescence in situ hybridization (FISH).
    Mayr D; Heim S; Werhan C; Zeindl-Eberhart E; Kirchner T
    Virchows Arch; 2009 Mar; 454(3):241-8. PubMed ID: 19169706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma.
    Lin SY; Wang YH; Hsu CY; Chen YJ; Lai CR; Hang JF
    Histopathology; 2021 Nov; 79(5):758-767. PubMed ID: 34036622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.